drugset / Trial / NCT00947245

Japanese Bridging Study Conducted in the United States

NCT00947245

Phase 1 Withdrawn Bristol-Myers Squibb
RandomizedParallel-groupTriple-blind

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics following single oral and multiple oral doses BMS-791325 in healthy Japanese subjects.

Timeline

Start
2014-10
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Beclabuvir Small molecule 300 mg Oral
Subject Beclabuvir Small molecule 900 mg Oral
Subject Beclabuvir Small molecule 1200 mg Oral